Navigation Links
Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference
Date:7/17/2008

SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that Dr. Graeme Moyle, Director of HIV Research, Chelsea and Westminster Hospital, will present results from the Phase 2a proof-of-concept monotherapy study of RDEA806, during an oral presentation at a late breaker session of the XVII International AIDS Conference in Mexico City on August 7, 2008. RDEA806 is the Company's novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human immunodeficiency virus (HIV).

Presentation Details

Date/Time: Thursday, August 7, 2008 from 2:30 p.m. - 4:00 p.m. CDT

Abstract Title: "Antiviral activity of RDEA806, a novel HIV non-nucleoside

reverse transcriptase inhibitor, in treatment of naive HIV patients"

Session Title: THAB04 - Late Breaker Track B, Session 2

Location: Centro Banamex -- Session Room 1 (Abstract #THAB0403)

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout
2. Craig Johnson Joins Ardea Biosciences Board of Directors
3. Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology
4. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
5. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
6. Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences
7. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
8. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
11. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014 Tigercat ... Phase 2 study evaluating the investigational oral NK-1 ... patients with severe, chronic itch who are unresponsive ... care, including topical steroids and antihistamines. ... in Visual Analog Scale (VAS) itch score from ...
(Date:12/15/2014)... 2014  GlassesOff Inc. (OTCBB: GLSO) announced today the ... independent director of the Company,s Board of Directors. ... as its CEO until its acquisition by Stanley ... transaction. Recognized as the inventor of the first Wi-Fi-based ... Wi-Fi -based RFID solutions focused on improving operational efficiency, ...
(Date:12/13/2014)... Maryland (PRWEB) December 12, 2014 Clarassance, ... today announced its new name: Therabron Therapeutics , ... therapy and bronchioles (a type of structure in the ... the company’s mission to develop novel protein therapeutics for ... of directors decided to change the name to mark ...
(Date:12/13/2014)... 2014 QuickSTAT is making significant investments ... Chain capabilities, and is delighted to announce the opening ... serve Life Science clients in the region. , QuickSTAT ... warehouse, will provide 24/7 transportation and logistics services, as ... patient-clinical specimens, API, following IATA rules and EU GDP ...
Breaking Biology Technology:Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2Quick Opens Office in France to Serve Life Science Community In France and Neighboring French-Speaking Countries 2
... -- JERUSALEM and NEEDHAM, Massachusetts, August 18, 2010, ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in ...
... Fuels, Inc., a company focused on commercially producing low-carbon ... has produced cellulosic methanol from the initial phase of ... using non-food biomass. The first phase of ... thermo-chemical process, which uses heat, pressure, and steam to ...
... VANCOUVER, Canada, Aug. 17 Xenon Pharmaceuticals Inc. announced ... trial evaluating its novel topical XEN402 therapy for the ... developed by Xenon as a topical ointment formulation and ... 1 study in normal human volunteers.  The product was ...
Cached Biology Technology:Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 2Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 3Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 4Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 5Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 6Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market 7Range Fuels Produces Cellulosic Methanol From First Commercial Cellulosic Biofuels Plant 2Xenon Pharmaceuticals Initiates a Phase 2 Clinical Trial in Post Herpetic Neuralgia (PHN) for Topical XEN402. 2
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here before: ... but can,t remember your password, site key or the answer ... your first grade teacher? Today, Hoyos ... app that will finally put an end to the ... 1U TM . 1U leverages a user,s smartphone to ...
(Date:12/10/2014)... Dec. 08, 2014 Research and Markets ... of the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration ... as rural banking and upgradation of the driver,s ... in the market. Besides the aforementioned projects, biometrics ...
(Date:12/4/2014)... Fla. , Dec. 3, 2014  Crossmatch™, ... today announced that its DigitalPersona ® Pro ... readers have been deployed throughout First Bank branch ... South Carolina and Virginia. First ... Southern Pines, North Carolina , ...
Breaking Biology News(10 mins):The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... foot ulcers are a common problem for diabetics and are ... leg amputations in these patients. There is currently no effective ... new research offers hope. French researchers found that diabetic ... prolinespecific molecules found in proteinshowed better wound healing over rats ...
... of the species that inhabit the world,s oceans may remain ... species have been described in the last decade than in ... November 15 in the Cell Press publication Current Biology ... of the worlda massive collaborative undertaking by hundreds of experts ...
... college-age video game enthusiasts teach young surgeons-in-training? ... University of Texas Medical Branch at Galveston (UTMB) ... the superior hand-eye coordination and hand skills gained ... needed to perform today,s most technologically-advanced robotic surgeries. ...
Cached Biology News:Arginine and proline enriched diet may speed wound healing in diabetes 2At least one-third of marine species remain undescribed 2Young gamers offer insight to teaching new physicians robotic surgery 2Young gamers offer insight to teaching new physicians robotic surgery 3
... The Rotofor purification system, 100-120 V, is ... liquid-phase isoelectric focusing (IEF). The system includes ... (60 ml) focusing chambers, chassis, harvesting apparatus, ... ampholytes (pH 3-10), 60 ml syringe, colored ...
... BCIP/NBT Chromogen system consists of ... in a single component,solution. The ... the presence of alkaline phosphatase ... minimal background noise. ,The System ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
SphingoStripsTM contain fifteen different biologically active, nitrocellulose-immobilized lipids at 100 pmol per spot, which can be assayed for protein binding and specificity using a simple blot ove...
Biology Products: